Shareholder proposals have been filed at major pharmaceutical companies by investors seeking information on the impacts of pricing policies on patient access to branded medicines. The investors cited a 2021 report by the Rand Corporation, which found that US branded drug prices were almost 3.5 times higher than prices in 32 OECD member countries.
The post Investors Cite Pharma Pricing Strategies as Human Rights Risk first appeared on Interfaith Center on Corporate Responsibility.
